Jason Kent

Cooley advised Chimerix (Nasdaq: CMRX), a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, on its definitive agreement to be acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) for $8.55 per share in cash – totaling approximately $935 million.

Cooley advised Sazerac, one of the world’s largest distilled spirits companies, on its agreement to acquire BuzzBallz, a woman-owned and family-operated distillery, winery and brewery in Texas.

New York – June 8, 2023 – Cooley advised 2045, an exclusive membership network for influential      professionals of color, on its launch and $4.2 million pre-seed financing. Partner Jason Kent led the Cooley team advising 2045.

Benchstrength led the funding round, with AAF Management and Connecticut Innovations also participating. NBA New Orleans Pelicans player CJ McCollum also participated as an angel investor.

Porter Braswell, a former Goldman Sachs alumnus, founded 2045 to provide a platform and community to empower influential professionals of color to feel seen, heard and valued. The company fills the current market void while addressing the less than 1% of the $50 billion pledged by American companies to support Black communities – and diversity, equity and inclusion efforts – following the death of George Floyd in 2020 . 2045 will provide the necessary tools and programs to help corporations better support, retain and promote a diverse workforce.

Cooley advised Mirum Pharmaceuticals on its $275 million aggregate principal amount of 4.00% convertible senior notes due 2029. Mirum is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Jason Kent and Jason Savich led the Cooley team.

Cooley advised the issuer for Mirum Pharmaceuticals’ $92 million follow-on offering of 4,000,000 shares of common stock at a public offering price of $23 per share. Mirum is a biopharmaceutical company developing and commercializing therapies for rare and debilitating liver diseases. Partner Jason Kent led the Cooley team.